Clinical Trials Logo

Thyroid Orbitopathy clinical trials

View clinical trials related to Thyroid Orbitopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03891043 Completed - Thyroid Orbitopathy Clinical Trials

Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy

Start date: August 2015
Phase: N/A
Study type: Interventional

Background: The activity of thyroid orbitopathy can be evaluated with CAS (Clinical Activity Score) based on 7 inflammatory signs. Selenium acts as an oxide-reducing agent in thioredoxin-reductase, and as an anti-inflammatory agent by reducing the hydroxy peroxide intermediates on the cyclo-oxygenase pathways. Increased oxidative stress has been observed in Graves' disease and therefore, by incorporating an antioxidant such as selenium in patients with mild thyroid ophthalmopathy, inflammatory activity could be reduced or inactivated. General Objective: To determine the clinical differences between patients with mild thyroid orbitopathy who were administered oral supplementation with selenium and patients who were administered oral placebo.